The MedaSystems platform enables pharmaceutical companies to respond to Expanded Access requests faster and more efficiently, design more effective clinical trials, enhance pre-approval regulatory submissions and capture real-world data. MedaSystems, a digital health software company, is excited to announce the completion of a $1.5 million pre-seed funding round led by specialist healthtech venture capital fund nina capital in conjunction with a group of strategic angel investors. Expanded Access allows patients with a serious or life-threatening condition, who have exhausted the standard of care and are not eligible to participate in clinical trials, to request access to investigational therapies that have not yet gained authorization from local regulatory authorities.MedaSystems Expanded Access platform connects physicians and pharmaceutical manufacturers to help patients gain access to investigational therapies.MedaSystems has developed a networked platform where pharmaceutical manufacturers and healthcare providers can collaborate on Expanded Access (also known as Managed Access or Compassionate Use) requests. The funds will enable MedaSystems to expand its product and engineering teams and speed the build out of its physician portal and real-world data gathering capabilities.